Risks of lithium toxicity in patients taking ACEi or ARB medications no greater than those taking beta blockers: Cohort study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Lithium remains the gold standard for treating and preventing manic episodes in bipolar disorder, but it has a narrow safety window. Studies have been conflicting on whether initiating an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) in patients taking lithium can result in lithium toxicity. Researchers examined this issue in a population-based cohort study in Ontario, Canada of adults 50 years and older who were co-prescribed an oral ACEi or ARB (n = 2,267) or a beta blocker (n = 2,110) while taking lithium. Beta-blockers were used as a comparator because they are prescribed for similar indications as ACEis and ARBs, but do not increase the risk of lithium toxicity. The researchers found no increase in 90-day risk of hospital admission with lithium toxicity during co-prescription of an ACEi or ARB with lithium compared with co-prescription of a beta-blocker. “These results support the continued use of ACE inhibitors or ARBs in lithium users when indicated; however, due to study limitations, we cannot draw firm conclusions,” the researchers wrote. “These findings should not be interpreted as evidence that ACE inhibitors or ARBs are universally safe with lithium, but rather that concomitant use may be feasible in selected patients when appropriate clinical caution and monitoring are undertaken.” Ahmadi, F., Muanda, F. T., McArthur, E., et al. (2026, Aug 5). Lithium toxicity from angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker co-prescription: A population-based cohort study. J Psychopharmacol, 2698811261473401. https://doi.org/10.1177/02698811261473401 Online ahead of print.
DOI: 10.1002/pu.31524
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7231622170
